1. American College of Obstetricians and Gynecologists. Editorial Board for Clinical Updates in Women’s Health Care. Clinical updates in women’s health care summary: liver disease: reproductive considerations. Obstet Gynecol 2017; 129: 236.
2.
Lee RH, Greenberg M, Metz TD, et al. Society for maternal-fetal medicine consult series# 53: intrahepatic cholestasis of pregnancy: replaces consult# 13, April 2011. Am J Obstet Gynecol 2021; 224: B2-B9.
3.
Arthuis C, Diguisto C, Lorphelin H, et al. Perinatal outcomes of intrahepatic cholestasis during pregnancy: an 8-year case-control study. PLoS One 2020; 15: e0228213.
4.
Peker A, Tanaçan A, İpek G, et al. Role of aspartate aminotransferase to platelet ratio in the prediction and prognosis of intrahepatic cholestasis of pregnancy: A case-control study from a tertiary center. Int J Gynecol Obstet 2024; 164: 656-661.
5.
Wai CT, Greenson JK, Fontana RJ, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
6.
Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-736.
7.
Tolunay HE, Kahraman NÇ, Varlı EN, et al. First-trimester aspartate aminotransferase to platelet ratio index in predicting intrahepatic cholestasis in pregnancy and its relationship with bile acids: A pilot study. Eur J Obstet Gynecol Reprod Biol 2021; 256: 114-117.
8.
Şaşmaz Mİ, Ayvaz MA, Dülger AC, et al. Aspartate-aminotransferase to platelet ratio index score for predicting HELLP syndrome. Am J Emerg Med 2020; 38: 459-462.
9.
Herrera CA, Manuck TA, Stoddard GJ, et al. Perinatal outcomes associated with intrahepatic cholestasis of pregnancy. J Matern Fetal Neonatal Med 2018; 31: 1913-1920.
10.
Shan D, Hu Y, Qiu P, et al. Intrahepatic cholestasis of pregnancy in women with twin pregnancy. Twin Res Hum Genet 2016; 19: 697-707.
11.
Cui D, Zhong Y, Zhang L, Du H. Bile acid levels and risk of adverse perinatal outcomes in intrahepatic cholestasis of pregnancy: a meta-analysis. J Obstet Gynaecol Res 2017; 43: 1411-1420.
12.
Ovadia C, Seed PT, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analysis. Lancet 2019; 393: 899-909.
13.
Lo JO, Shaffer BL, Allen AJ, et al. Intrahepatic cholestasis of pregnancy and timing of delivery. J Matern Fetal Neonatal Med 2015; 28: 2254-2258.
14.
Chang X, Lv C, Wang B, et al. The utility of PIR classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis. Hepatology 2024; 79: 425-437.
15.
Chen Y, Zhang H, Ning W, et al. The impact of intrahepatic cholestasis on pregnancy outcomes: a retrospective cohort study. BMC Gastroenterol 2023; 23: 16.
16.
Brouwers L, Koster MP, Page-Christiaens GC, et al. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. Am J Obstet Gynecol 2015; 212: 100.e1-7.
17.
Tolunay HE, Kahraman NC, Varli EN, et al. Can first-trimester AST to platelet ratio index scores predict HELLP syndrome.
18.
J Coll Physicians Surg Pak 2021; 31: 188-192.
19.
Jelski W, Piechota J, Orywal K, Mroczko B. The alterations in alcohol dehydrogenase activity in the sera of women with intrahepatic cholestasis of pregnancy. Anticancer Res 2020; 40: 1997-2001.
20.
Piechota J, Jelski W, Orywal K, Mroczko B. The comparison of total bile acid concentration and alcohol dehydrogenase activity as markers of intrahepatic cholestasis of pregnancy. Acta Biochim Pol 2022; 69: 173-176.
21.
Piechota J, Jelski W, Orywal K, Mroczko B. The alcohol dehydrogenase isoenzyme (ADH I) as a marker of intrahepatic cholestasis of pregnancy. Sci Rep 2022; 12: 11071.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
